tirzepatide cardiovascular outcomes trial results august 2025 A network meta-analysis backed weight-loss benefits with several GLP-1 receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Preliminary results on the Tirzepatide

rd EASD annual meeting of the european association for the study of diabetes

Any suspected adverse reactions to medicines or supplements should be reported to the MHRA through the Yellow Card scheme

Monitoring and Documentation Symptom Diary : Keep a detailed record of your dizziness episodes, including when they occur, their duration, severity, and any activities or foods that might be related

A woman who took Ozempic to lose weight no longer experienced mast cell problems

These can include nausea, acid reflux, constipation or diarrhea, and rarely, a type of thyroid cancer called medullary thyroid cancer

These structural modifications allow tirzepatide to engage the GIP receptor with high potency while also maintaining agonist activity at the GLP-1 receptor